BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20514304)

  • 21. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
    Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
    Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ile105Val GSTP1 polymorphism and susceptibility to colorectal carcinoma in Bulgarian population.
    Vlaykova T; Miteva L; Gulubova M; Stanilova S
    Int J Colorectal Dis; 2007 Oct; 22(10):1209-15. PubMed ID: 17404745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
    Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
    PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
    Kanai M; Yoshioka A; Tanaka S; Nagayama S; Matsumoto S; Nishimura T; Niimi M; Teramukai S; Takahashi R; Mori Y; Kitano T; Ishiguro H; Yanagihara K; Chiba T; Fukushima M; Matsuda F
    Cancer Epidemiol; 2010 Apr; 34(2):189-93. PubMed ID: 20308030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
    Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
    Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
    J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
    BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China.
    Ge J; Tian AX; Wang QS; Kong PZ; Yu Y; Li XQ; Cao XC; Feng YM
    PLoS One; 2013; 8(6):e67589. PubMed ID: 23826324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of glutathione-S-transferase gene polymorphism and lipoprotein subclasses in hemodialysis patients.
    Vekic J; Zeljkovic A; Jelic-Ivanovic Z; Damjanovic T; Suvakov S; Matic M; Savic-Radojevic A; Simic T; Spasojevic-Kalimanovska V; Gojkovic T; Spasic S; Dimkovic N
    Clin Biochem; 2014 Apr; 47(6):398-403. PubMed ID: 24291050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between GSTP1 Val allele and H. pylori infection, smoking and alcohol consumption and risk of gastric cancer among the Chinese population.
    Zhang Y; Sun LP; Xing CZ; Xu Q; He CY; Li P; Gong YH; Liu YP; Yuan Y
    PLoS One; 2012; 7(10):e47178. PubMed ID: 23077566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A molecular epidemiological study on the relationship between the polymorphism of GSTP1 and susceptibility to gastric cancer in northern Chinese].
    Zhang Y; Sun LP; Chen W; Bai XL; Liu J; Wang XG; Liu YP; Yuan Y
    Yi Chuan; 2007 Mar; 29(3):293-300. PubMed ID: 17369149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
    Keam B; Im SA; Han SW; Ham HS; Kim MA; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Heo DS; Kim WH; Bang YJ
    BMC Cancer; 2008 May; 8():148. PubMed ID: 18505590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma.
    Atanaskovic L; Cikota-Aleksic B; Tarabar O; Trimcev J; Zivanovic-Ivic A; Marjanovic S; Magic Z
    J BUON; 2016; 21(6):1459-1465. PubMed ID: 28039708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese.
    Zhong SL; Zhou SF; Chen X; Chan SY; Chan E; Ng KY; Duan W; Huang M
    Eur J Pharm Sci; 2006 May; 28(1-2):77-85. PubMed ID: 16488119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.
    Yokomizo A; Yamamoto K; Kinukawa N; Tsunoda T; Koga H; Naito S
    Int J Urol; 2007 Jun; 14(6):500-4. PubMed ID: 17593093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.